Astex Bags Another Cancer Deal With MSD, This Time For ‘Undruggable’ p53 Target
Gets $35m Upfront
The UK-based biotech will license its Pyramid platform to MSD to develop anticancer compounds targeting p53, a key transcription factor dubbed the ‘guardian of the genome’ that has proven highly complex and challenging to drug.
